[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.41.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1996

Chemoreduction in the Initial Management of Intraocular Retinoblastoma

Author Affiliations

From the Ocular Oncology Service, Wills Eye Hospital Service, Thomas Jefferson University, Philadelphia, Pa (Drs C. Shields, De Potter, and J. Shields); and the Division of Oncology, The Children's Hospital of Philadelphia (Drs Himelstein, Meadows, and Maris).

Arch Ophthalmol. 1996;114(11):1330-1338. doi:10.1001/archopht.1996.01100140530002
Abstract

Background:  Chemoreduction is a method of reducing tumor volume to allow for more focused, less damaging therapeutic measures.

Objective:  To determine whether chemoreduction could be used to decrease the size of retinoblastoma so that enucleation or external beam radiotherapy could be avoided and more conservative modalities employed.

Methods:  A prospective pilot study was performed to assess the effectiveness of a 2-month chemoreduction regimen of vincristine sulfate, etoposide, and carboplatin in patients with retinoblastoma. The study included 20 patients with 54 tumors in 31 eyes.

Results:  At the initial examination, the mean tumor base was 12 mm and the thickness, 7 mm. Vitreous seeds were present in 14 eyes (45%). A secondary retinal detachment was present in 24 eyes (77%) and, when present, involved a mean of 71% of the retina. In 11 eyes (36%) the retina was totally detached with serous subretinal fluid. After 2 months of chemoreduction, all 54 tumors showed regression in size, and 48 (89%) showed evidence of calcification. The mean tumor base was 8 mm and the thickness, 4 mm. Overall, there was a mean 35% decrease in base and 49% decrease in thickness of the tumor at the end of the treatment period. A complete response was found in 25 tumors (46%) and a partial response in 29 (54%). The subretinal fluid had resolved completely in 50% of the cases (12/24 eyes), and, in the 11 eyes with total retinal detachment, the subretinal fluid had completely resolved, leaving flat retina, in 6 eyes (54%). The vitreous seeds demonstrated some degree of regression in all cases, and in 5 eyes there was 90% to 100% calcification of the seeds. Short-term systemic toxic effects were mild (transient bone marrow suppression). Enucleation was avoided in all cases; external beam radiotherapy was necessary in 9 eyes because of diffuse vitreous seeds. The remaining 22 eyes were treated with local methods after chemoreduction.

Conclusion:  Tumor shrinkage with chemoreduction may allow treatment with less invasive measures, such as cryotherapy, laser photocoagulation, thermotherapy, or plaque radiotherapy, thereby avoiding enucleation and external beam radiotherapy.

References
1.
Shields JA, Shields CL. Intraocular Tumors: A Text and Atlas . Philadelphia, Pa: WB Saunders Co; 1992:305-391.
2.
Ellsworth RM.  The practical management of retinoblastoma . Trans Am Ophthalmol Soc . 1969;67:463-534.
3.
Shields JA, Shields CL.  Current management of retinoblastoma . Mayo Clin Proc . 1994;69:50-56.Article
4.
White L.  The role of chemotherapy in the treatment of retinoblastoma . Retina . 1983;3:194-199.Article
5.
White L.  Chemotherapy in retinoblastoma: current status and future directions . Am J Pediatr Hematol Oncol . 1991;13:189-201.Article
6.
White L.  Chemotherapy for retinoblastoma: where do we go from here? Ophthalmic Paediatr Genet . 1991;12:115-130.Article
7.
Pratt CB, Crom DB, Howarth C.  The use of chemotherapy for extraocular retinoblastoma . Med Pediatr Oncol . 1985;13:330-333.Article
8.
Kingston JE, Hungerford JL, Plowman PN.  Chemotherapy in metastatic retinoblastoma . Ophthalmic Paediatr Genet . 1987;8:69-72.Article
9.
Keith CG.  Chemotherapy in retinoblastoma management . Ophthalmic Paediatr Genet . 1988;10:93-98.Article
10.
Goble RR, McKenzie J, Kingston JE, Plowman PN, Hungerford JL.  Orbital recurrence of retinoblastoma successfully treated by combined therapy . Br J Ophthalmol . 1990;74:97-98.Article
11.
Doz F, Khelfaoui F, Mosseri V, et al.  The role of chemotherapy in orbital involvement of retinoblastoma: the experience of a single institution with 33 patients . Cancer . 1994;74:722-732.Article
12.
Fellezou JY, Fauchon F, Chiras J.  Intraarterial infusion of carboplatin in the treatment of malignant gliomas: a phase II study . Neoplasma . 1989;36:349-352.
13.
Dropcho EJ, Rosenfeld SS, Marawetz RB, et al.  Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas . J Clin Oncol . 1992;10:452-458.
14.
Lamer JM, Phillips CD, Dion JE, Jensen ME, Newman SA, Jane JA.  A phase 1-2 trial of superselective carboplatin, low-dose infusional 5-fluorouracil and concurrent radiation for high-grade gliomas . Am J Clin Oncol . 1995;18:1-7.Article
15.
Chamberlain MC, Barba D, Kormanik P, Berson A, Saunders WM, Shea MC.  Concurrent cisplatin therapy and iodine 125 brachytherapy for recurrent malignant brain tumors . Arch Neurol . 1995;52:162-167.Article
16.
Rubin CM, Robinson LL, Cameron JD, et al.  Intraocular retinoblastoma group V: an analysis of prognostic factors . J Clin Oncol . 1985;3:680-685.
17.
Singh AD, Garway-Heath D, Love S, Plowman PN, Kingston JE, Hungerford JL.  Relationship of regression pattern to recurrence in retinoblastoma . Br J Ophthalmol . 1993;77:12-16.Article
18.
Shields JA, Shields CL, Donoso LA, Lieb WA.  Changing concepts in the management of retinoblastoma . Ophthalmic Surg . 1990;21:72-76.
19.
Sagerman RH, Cassady JR, Tretter P, Ellsworth RM.  Radiation induced neoplasia following external beam therapy for children with retinoblastoma . AJR Am J Roentgenol . 1969;105:529-535.Article
20.
Abramson DH, Ellsworth RM, Kitchin FD, Tung G.  Second nonocular tumors in retinoblastoma survivors: are they radiation-induced? Ophthalmology . 1984;91:1351-1355.Article
21.
Draper GJ, Sanders BM, Kingston JE.  Second primary neoplasms in patients with retinoblastoma . Br J Cancer . 1986;53:661-671.Article
22.
Tucker MA, D'Angio GJ, Boice JD Jr, et al.  Bone sarcomas linked to radiotherapy and chemotherapy in children . N Engl J Med . 1987;317:588-593.Article
23.
Eng C, Li FP, Abramson DH, et al.  Mortality from second tumors among long-term survivors of retinoblastoma . J Natl Cancer Inst . 1993;85:1121-1128.Article
24.
Meadows AT.  Risk factors for second malignant neoplasms: report from the late effects study group . Bull Cancer . 1988;75:125-130.
25.
Roarty JD, McLean IW, Zimmerman LE.  Incidence of second neoplasms in patients with bilateral retinoblastoma . Ophthalmology . 1988;95:1583-1587.Article
26.
Shields CL, Shields JA, De Potter P, et al.  Plaque radiotherapy in the management of retinoblastoma: use as a primary and secondary treatment . Ophthalmology . 1993;100:216-224.Article
27.
Shields CL, Shields JA, Minelli S, et al.  Regression of retinoblastoma after plaque radiotherapy . Am J Ophthalmol . 1993;115:181-187.
28.
Shields JA, Shields CL, Parsons H, Giblin ME.  The role of photocoagulation in the management of retinoblastoma . Arch Ophthalmol . 1990;108:205-208.Article
29.
Shields JA.  The expanding role of laser photocoagulation for intraocular tumors: the 1993 Christian Zweng Memorial Lecture . Retina . 1994;14:310-322.Article
30.
Shields CL, Shields JA, Kiratli H, De Potter P.  Treatment of retinoblastoma with indirect ophthalmoscopic laser photocoagulation . J Pediatr Ophthalmol Strabismus . 1995;32:317-322.
31.
Shields JA, Parsons H, Shields CL, Giblin ME.  The role of cryotherapy in the management of retinoblastoma . Am J Ophthalmol . 1989;108:260-264.
32.
Shields JA, Shields CL, Sivalingam V.  Decreasing frequency of enucleation in patients with retinoblastoma . Am J Ophthalmol . 1989;108:185-188.
33.
Sanders BM, Draper GJ, Kingston JE.  Retinoblastoma in Great Britain 1969-1980: incidence, treatment, and survival . Br J Ophthalmol . 1988;72:576-583.Article
34.
Kupfer C.  Retinoblastoma treated with intravenous nitrogen mustard . Am J Ophthalmol . 1953;36:1721-1723.
35.
Reese AB, Hyman GA, Merriam GR Jr, Forrest AW, Kligerman MM.  Treatment of retinoblastoma by radiation and triethylenemelamine . Arch Ophthalmol . 1955;53:505-513.Article
36.
Skeggs DBL, Williams IG.  The treatment of advanced retinoblastoma by means of external irradiation combined with chemotherapy . Clin Radiol . 1966;17:169-172.Article
37.
Hyman GA, Ellsworth RM, Feind CR, Tretter P.  Combination therapy in retinoblastoma: a 15 year summary of methods and results . Arch Ophthalmol . 1968;80:744-746.Article
38.
Freeman CR, Esseltine DL, Whitehead VM, Chevalier L, Little JM.  Retinoblastoma: the case for radiotherapy and for adjuvant chemotherapy . Cancer . 1980;46:1913-1918.Article
39.
Judisch GF, Apple DJ, Fratkin JD.  Retinoblastoma: a survival 12 years after treatment for metastastic disease . Arch Ophthalmol . 1980;98:711-713.Article
40.
Advani SH, Rao SR, lyer RS, Pai SK, Kurkure PA, Nair CN.  Pilot study of sequential combination chemotherapy in advanced and recurrent retinoblastoma . Med Pediatr Oncol . 1994;22:125-128.Article
41.
Abramson DH.  Retinoblastoma: diagnosis and management . Cancer . 1982;32:130-140.Article
42.
Murphree AL, Munier FL.  Retinoblastoma . In: Ryan SJ, ed. Retina . St Louis, Mo: Mosby-Year Book; 1994:571-626.
43.
Frezzotti R, Hadjistilianou T, Castello M.  The role of chemotherapy in the treatment of intraocular retinoblastoma . In: Frezzotti R, Balestrazzi E, Falco L, Esente S, eds. International Symposium on Intraocular and Epibulbar Tumors . Bologna, Italy: Monduzzi Editore SpA; 1994:29-34.
44.
Chan HSL, Thorner PS, Haddad G, Gallie BL.  Effect of chemotherapy on intraocular retinoblastoma . Int J Pediatr Health . 1995;2:269-281.
45.
Inomata M, Kaneko A.  Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay . Jpn J Cancer Res . 1987;78:858-868.
46.
Seregard S, Kock E, Trampe E.  Intravitreal chemotherapy for recurrent retinoblastoma in an only eye . Br J Ophthalmol . 1995;79:194-195.Article
×